Agilent Technologies Upgrades Cerity CDS for Pharmaceutical QA/QC
News Dec 20, 2005
Agilent Technologies Inc. has announced the release of Cerity CDS A.02.03, a chromatography data system for pharmaceutical quality assurance/quality control laboratories, designed to enhance workflows and facilitate compliance of pharmaceutical QA/QC labs of all sizes.
"We’ve designed a complete package for today’s pharmaceutical QA/QC lab that adapts easily to laboratory workflow to optimize efficiency and productivity, while also providing close integration with other internal and external systems," said Gunter Nill, general manager, Pharma Solutions Business, Agilent Life Sciences and Chemical Analysis.
Cerity CDS is designed to offer fully automated validation tools for analytical hardware qualification and verification, as well as software qualification.
Cerity CDS offers many features to facilitate FDA 21 CFR Part 11 compliance, including version control, inherent data integrity and an automatic, fully-traceable audit trail to ensure that no records can be overwritten.
It provides for Level-4 instrument control, including security features such as active handshake, error checking, automated tracking of serial numbers and firmware revisions, and advanced diagnostics.
Cerity A.02.03 scales up seamlessly from standalone, single-user configurations to distributed multi-user, multi-instrument configurations for labs with 100 instruments or more.
"We’re protecting customers’ investments in Cerity for Pharmaceutical QA/QC by building on technology such as instrument control through LAN or Oracle-based data management," Nill added.
"Cerity CDS for Pharmaceutical QA/QC also provides for integration of leading-edge technologies."
Customers with a current Agilent Support Contract will receive a free upgrade to Cerity CDS A.02.03 software.
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE